Search Results - "Witherby, S. M."

Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study by Lopresti, M. L., Bian, J. J., Sakr, B. J., Strenger, R. S., Legare, R. D., Fenton, M., Witherby, S. M., Dizon, D. S., Pandya, S. V., Stuckey, A. R., Edmondson, D. A., Gass, J. S., Emmick, C. M., Graves, T. A., Cutitar, M., Olszewski, A. J., Sikov, W. M.

“…Purpose In HER2-positive breast cancer (HER2+ BC), neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response…”
Get full text

Special issues related to breast cancer adjuvant therapy in older women by Witherby, S.M., Muss, H.B.

“…Increasing age remains the major risk factor for breast cancer and more than half of all breast cancers in North America and the European Union occur in women…”
Get full text

Update in medical oncology for older patients: focus on breast cancer: management of early breast cancer by Witherby, S M, Muss, Hyman B

“…Breast cancer is a disease of older women, and its incidence continues to rise with the growth and aging of the U.S. population. Elderly women have frequently…”
Get full text

Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group by Fenton, M, Sakr, B. J, Witherby, S. M, Bian, J. J, Strenger, R. S, Lopresti, M. L, Legare, R. D

“…Purpose In HER2-positive breast cancer (HER2+ BC), neoadjuvant chemotherapy (NACT) with dual HER2-targeted therapy achieves high pathologic complete response…”
Get full text

Update in Medical Oncology for Older Patients: Focus on Breast Cancer by Witherby, S. M., Muss, Hyman B.

Get full text